Bitcoin

In the current bearish macro environment with extreme fear (F&G 11), any positive non-crypto news can provide a slight tailwind for risk assets, though the effect is negligible. Long-term, antibiotic innovation supports public health, which indirectly benefits economic stability, but this is too remote to affect crypto prices.

A natural depsipeptide antibiotic called manikomycin from Streptomyces rimosus was discovered to bind the E-site of the bacterial ribosome.

Manikomycin Discovery Reduces Pandemic Risk, Dampens Crypto’s Lockdown Rally Narrative

New Antibiotic Discovery Reduces Pandemic Risk – Bearish for Crypto's 'Lockdown Rally' Narrative

Historically, health crises (e.g., COVID-19, Ebola) cause short-term capital flight from risk assets, but crypto often recovers quickly as central banks respond with stimulus. However, this outbreak is smaller and localized, so the direct macro impact is minimal. The bigger picture is that persistent fear narratives (war, disease, recession) keep retail sidelined and institutional capital hesitant, reinforcing the current bearish trend.

Clinical trials for treatments against Ebola Bundibugyo virus are poised to launch quickly in the Democratic Republic of the Congo and Uganda amid the current outbreak.